Garnett W R
School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0533, USA.
Am J Health Syst Pharm. 1998 Nov 1;55(21):2268-79. doi: 10.1093/ajhp/55.21.2268.
The safety of proton-pump inhibitors (PPIs) for long-term use is reviewed. PPIs are being used with increasing frequency to inhibit secretion of gastric acid in order to treat acid-related disorders such as gastroesophageal reflux disease and peptic ulcer disease. Some patients may require long-term acid suppressive treatment to control the symptoms of their disease, which raises questions about the long-term safety of PPIs. A thorough literature search was conducted, and the clinical consequences of sustained hypergastrinemia induced by all antisecretory therapy, the consequences of atrophic gastritis in patients infected with Helicobacter pylori, the effects of hypochlorhydria on bacterial overgrowth and nutrient absorption, and possible interactions of PPIs with other drugs were identified as areas of concern with long-term use of PPIs. Short- and long-term studies showed that PPIs have a wide safety margin and a favorable adverse-event profile with few drug interactions. Available data support the short- and long-term safety of PPIs.
对质子泵抑制剂（PPIs）长期使用的安全性进行了综述。PPIs被越来越频繁地用于抑制胃酸分泌，以治疗诸如胃食管反流病和消化性溃疡病等酸相关性疾病。一些患者可能需要长期的抑酸治疗来控制其疾病症状，这引发了关于PPIs长期安全性的问题。进行了全面的文献检索，并确定了所有抗分泌疗法引起的持续性高胃泌素血症的临床后果、幽门螺杆菌感染患者萎缩性胃炎的后果、胃酸过少对细菌过度生长和营养吸收的影响以及PPIs与其他药物可能的相互作用，这些都是PPIs长期使用时需要关注的领域。短期和长期研究表明，PPIs具有广泛的安全范围和良好的不良事件特征，药物相互作用较少。现有数据支持PPIs的短期和长期安全性。
